posted
This stock should be trading around $0.80/share and once they finish phase II trials, they should be at $20/share...look at their site, http://www.NutraPharma.com -- and look at its comprables (Biogen and Amylin)
Posts: 91 | Registered: Oct 2004
| IP: Logged |
posted
well they have 0 in revenues but i guess if the cobra venom works out it may be worth somthing. other then that its junk for now..we'll see.
Posts: 1045 | From: novato,ca,usa | Registered: Aug 2003
| IP: Logged |
quote:Originally posted by metal1: well they have 0 in revenues but i guess if the cobra venom works out it may be worth somthing. other then that its junk for now..we'll see.
Posts: 12 | From: aventura, fl. usa | Registered: Oct 2004
| IP: Logged |
quote:Originally posted by metal1: well they have 0 in revenues but i guess if the cobra venom works out it may be worth somthing. other then that its junk for now..we'll see.
To begin with NPHC refused .80 cents a share as a buy out, The stock is worth a great deal more. It won't be long before you see it rise a great deal more, Their trials are great , The news has been very good in recent months. I think we have a tiger by the tail. I'm long in this stock and buying as much as i can afford. I can see $3to $5 very easily. Their MS and HIV drugs can be block busters. You need to be patient stocks like this don't come along very often. Some large pharma company will jump on them. If the fda puts them on fast track on any of the drugs---its away they go. The stock is doing something the past few days. The shorts will be screaming shortly. That's my opinion. Good luck
Posts: 12 | From: aventura, fl. usa | Registered: Oct 2004
| IP: Logged |
quote:Originally posted by metal1: well they have 0 in revenues but i guess if the cobra venom works out it may be worth somthing. other then that its junk for now..we'll see.
Wow----did you see news release on the ms trials. This is going to fly high. Saw the stock at 60 cents just a while ago. I'd say it's time to jump on this baby..
Posts: 12 | From: aventura, fl. usa | Registered: Oct 2004
| IP: Logged |
posted
great news out today about the MS reults. It just doesn't get any better. this stock should continue to climb with all the great products that nphc has coming down the pipe.
quote:Originally posted by biotechguy0331: This stock should be trading around $0.80/share and once they finish phase II trials, they should be at $20/share...look at their site, http://www.NutraPharma.com -- and look at its comprables (Biogen and Amylin)
posted
the problem with these develpment stage stocks is obviously timing. you don't want to get in too early because you end up bleeding away share price as they dilute the stock to finance their research. since they have 0 in revenues and it will take a while for any products to get to market i think one can sit back and be patient with this one. as far as a target buy price? it looks like the last real bounce was in the low .20's so we'll see what happens if it gets there again....
Posts: 1045 | From: novato,ca,usa | Registered: Aug 2003
| IP: Logged |
posted
if they get approval for the identikits, you will probably see revenues in the hundreds of millions. these kits are great for the cattle industry as well as tb and other infectious diseases. with the mad cow going around the kits should be hot both here and abroad. then they should have boat loads of money to fund the other trials of the hiv and ms from your identikit sales.
quote:Originally posted by metal1: the problem with these develpment stage stocks is obviously timing. you don't want to get in too early because you end up bleeding away share price as they dilute the stock to finance their research. since they have 0 in revenues and it will take a while for any products to get to market i think one can sit back and be patient with this one. as far as a target buy price? it looks like the last real bounce was in the low .20's so we'll see what happens if it gets there again....
posted
imo---if the identikits get approved this stock will take off
quote:Originally posted by thebigpoppa: if they get approval for the identikits, you will probably see revenues in the hundreds of millions. these kits are great for the cattle industry as well as tb and other infectious diseases. with the mad cow going around the kits should be hot both here and abroad. then they should have boat loads of money to fund the other trials of the hiv and ms from your identikit sales.
quote:Originally posted by metal1: the problem with these develpment stage stocks is obviously timing. you don't want to get in too early because you end up bleeding away share price as they dilute the stock to finance their research. since they have 0 in revenues and it will take a while for any products to get to market i think one can sit back and be patient with this one. as far as a target buy price? it looks like the last real bounce was in the low .20's so we'll see what happens if it gets there again....
You sound like a chartist. Suppose it doesn't retreat to the low 20's. If it trades in the 40's, 50's----what would entice you to buy. What is your intended buy signal? What kind of sustained volume, up or down are you looking for? It sounds like i'm picking your brain, i am.
Posts: 12 | From: aventura, fl. usa | Registered: Oct 2004
| IP: Logged |
quote:Originally posted by melee: You sound like a chartist. Suppose it doesn't retreat to the low 20's. If it trades in the 40's, 50's----what would entice you to buy. What is your intended buy signal? What kind of sustained volume, up or down are you looking for? It sounds like i'm picking your brain, i am.
Posts: 12 | From: aventura, fl. usa | Registered: Oct 2004
| IP: Logged |
posted
without a doubt this stock is poised for a breakout. you dont have to be a rocket sceintist or a chartist to figure it out.facts: a new investor relations company. identikit ready for fda approval. cobra venom cloned having enough product to meet any volume for hiv treatment, and the just released report RPI-78M animal model for MS.your comments please.
Posts: 1 | Registered: Oct 2004
| IP: Logged |
posted
according to ceocast.com, hiv phase 2 trials should be out around first qtr 2005. cant wait.
quote:Originally posted by biotechguy0331: This stock should be trading around $0.80/share and once they finish phase II trials, they should be at $20/share...look at their site, http://www.NutraPharma.com -- and look at its comprables (Biogen and Amylin)
posted
Hey, I'm only 16 but have already almost tripled my money by investing in ADSX and SIRI and I am always looking for good stocks. I read the stock post a few days ago and this thing looks like a GEM. My question is when do oyu think would be the best time to get in on this, I think early DEC at latest. Any thoughts?
Posts: 33 | Registered: Aug 2004
| IP: Logged |
posted
Hey, I'm only 16 but have already almost tripled my money by investing in ADSX and SIRI and I am always looking for good stocks. I read the stock post a few days ago and this thing looks like a GEM. My question is when do oyu think would be the best time to get in on this, I think early DEC at latest. Any thoughts?
posted
well, more "good news" came out and the stock dropped like a rock late last week. i think that tells you that there is no hurry to jump in. i could be wrong of course. i also noticed the company stated that its their subsidiary which has the Identikit Technology so they would actually get the revenue since its publicly traded. Nutra would benefit from the share appeciation of its equity holdings(majority owned as they state) i looked at a quote for Infectech(IFEC) and didn't see a story under that symbol. wierd.
[This message has been edited by metal1 (edited October 18, 2004).]
posted
some day a company WILL find an HIV cure and its stock will go up 100 fold in a day. but who knows when? maybe this will be the one
Posts: 1045 | From: novato,ca,usa | Registered: Aug 2003
| IP: Logged |
posted
i found a website for infectech. http://www.infectech.com/ does anyone know of a receptapharm website? I couldn't find it.
quote:Originally posted by metal1: well, more "good news" came out and the stock dropped like a rock late last week. i think that tells you that there is no hurry to jump in. i could be wrong of course. i also noticed the company stated that its their subsidiary which has the Identikit Technology so they would actually get the revenue since its publicly traded. Nutra would benefit from the share appeciation of its equity holdings(majority owned as they state) i looked at a quote for Infectech(IFEC) and didn't see a story under that symbol. wierd.
[This message has been edited by metal1 (edited October 18, 2004).]
quote:Originally posted by metal1: some day a company WILL find an HIV cure and its stock will go up 100 fold in a day. but who knows when? maybe this will be the one
The web site for nutra pharma is----nutra pharma.com they have all the news releases.
Posts: 12 | From: aventura, fl. usa | Registered: Oct 2004
| IP: Logged |
posted
would like to see nutrapharma have the cure. that would be great... if their hiv drug does as well as it sounds from other news releases about it, I believe this stock would go well beyond 100 times it is trading today.
quote:Originally posted by melee: The web site for nutra pharma is----nutra pharma.com they have all the news releases.
quote:Originally posted by melee: The web site for nutra pharma is----nutra pharma.com they have all the news releases.
I AM highly confused, I have been watching this stock for a week now and the VOLUME TODAY WAS 500 SHARES. I just dont understand the sex appeal of this stock, no one knows about it and you guys say it could go up to $20.00, please explain?
quote:Originally posted by tfct24: I AM highly confused, I have been watching this stock for a week now and the VOLUME TODAY WAS 500 SHARES. I just dont understand the sex appeal of this stock, no one knows about it and you guys say it could go up to $20.00, please explain?
Did you go to nutra pharma.com? That's their website. It will give you all the news. More news will come out that will push the stock up. Their new client relations people will be working to tell the story. When the stock is trading 600,00 to 700,000 a day and more what did you think? The slow day today is the quite before the storm. You may think it won't fly. I do think it will? My money is in this stock. I think it will be a very, very big winner. Human trials will start soon, and the big companies will be licking their chops to get the patents. Stop watching and start buying it's dirt cheap.
Posts: 12 | From: aventura, fl. usa | Registered: Oct 2004
| IP: Logged |
posted
This stock has got to be undervalued -- It seems to have a good pipeline and great intellectual property. They also announced they have funding -- Any ideas as to why it isn't on anyone's radar screen?
Posts: 91 | Registered: Oct 2004
| IP: Logged |
posted
Thanks metal1 -- That is true -- but they've come out with some pretty fantastic results about their HIV and MS studies -- I've seen other companies in the same situation sitting at $5-$10/shr...
Posts: 91 | Registered: Oct 2004
| IP: Logged |
posted
their hiv drug is not even in phase 2 as of their last 10q if i remember right. it may still be a while before any real new info comes out. they will need lots of money to continue all their testing. more money = more dillution.
Posts: 1045 | From: novato,ca,usa | Registered: Aug 2003
| IP: Logged |
Nutra Pharma Reports Discovery of New Gene Involved in Multiple Sclerosis
BOYNTON BEACH, Fla.--(BUSINESS WIRE)--Dec. 19, 2005--Nutra Pharma Corp., (OTCBB:NPHC) a biotechnology holding company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis (MS) has announced that their continuing microarray studies have identified a new gene involved in the disease process of Multiple Sclerosis. Although the gene and some of its functions are already known, this is the first evidence of involvement with the disease state of MS. The research also provides evidence that RPI-78M modulates the expression of this gene in laboratory assays. RPI-78M is the lead drug candidate of Nutra Pharma's holding, ReceptoPharm, Inc. and is being studied in preclinical assays for its efficacy in treating MS.
Eno Research and Development, Inc. (ERDI) was contracted by Nutra Pharma to analyze samples of immune cells and brain lesion material from MS patients, with and without the addition of RPI-78M. They measured the changes in gene expression that occurred with treatment. Statistical evaluation of the data revealed more than sixty genes with significant changes in expression as a result of exposure to RPI-78M. In analyzing the affected genes, at least thirty of them may have a specific role in the progression of the disease and symptoms of MS.
"While RPI-78M alters the regulation of genes known to be involved with MS, we are especially excited by the modulation of this gene previously unassociated with MS at all. Work to further characterize the involvement of this gene in the disease progression of MS is ongoing," commented James Flowers, President and Chief Scientific Officer of Eno Research and Development, Inc. (ERDI). "The data from this study suggests that RPI-78M may aid the patient in reversing some of the damage caused by MS. It is notable that if these results were replicated in the patient population it may greatly reduce the severity of the disease," he concluded.
There has been a great deal of interest surrounding research in Multiple Sclerosis therapies. There are currently four drugs on the market for the treatment of the disease. A fifth drug, Tysabri, was voluntarily pulled from the marketplace in February by the drug's manufacturers, Biogen-Idec (Nasdaq: BIIB - News) and Elan (NYSE: ELN - News).
"We are working diligently with ERDI to bring this information to the scientific community," commented Rik J Deitsch, Chief Executive Officer of Nutra Pharma. "We expect to present the data at related conferences and to seek publication of the finished work. We are also seeking to patent this gene as a potential new target for MS therapies. If we are successful, the patent may provide revenues through partnerships and licensing. These studies, when coupled with the positive results in the animal models, create substantial evidence of the drug's effects against MS," he added.
About Multiple Sclerosis: Multiple Sclerosis (MS) is an autoimmune disease in which the immune system, the body's principal defense against foreign substances such as bacteria, mistakenly attacks normal tissues of the central nervous system. It afflicts approximately 400,000 people in the United States and more than 2.5 million worldwide. Specifically, the disease results in damage to a fatty tissue called myelin that surrounds and protects nerve fibers, creating scarring (sclerosis) that interferes with the normal transmission of nerve impulses. This damage, in turn, leads to a variety of chronic and highly individual and unpredictable neurological symptoms, ranging from movement and balance problems to vision impairment. The disease is largely caused by activation of a specific subset of the patient's own white blood cells, T-cells that then attack the myelin and are largely responsible for disease progression.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the development of drugs for HIV and Multiple Sclerosis ("MS"). The Company's other holding Infectech, Inc., is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
ReceptoPharm is a bio-pharmaceutical company developing proprietary therapeutic proteins for the treatment of several chronic, life-threatening viral, auto-immune and neuro-degenerative disorders, specifically including Rabies, HIV, and Myasthenia gravis (MG).
Eno Research and Development, Inc. (ERDI) is a full-service contract research organization located in Hillsborough, North Carolina, near Research Triangle Park. ERDI offers a wide range of pre-clinical development services to pharmaceutical, biotechnology, medical device, animal health and nutraceutical companies. The scientific staff of ERDI possess expertise in biotechnology, pharmacology, tumor biology, synthetic and analytical chemistry, in silico modeling of drug interaction/binding and rational drug design, as well as microarray technology and bioinformatics. With this expertise, ERDI can offer services ranging from lead discovery through New Drug Applications.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The information presented should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Posts: 91 | Registered: Oct 2004
| IP: Logged |
posted
Apparently they are ready to start phase III for AMN -- they have been releasing good news lately, which i'm certain will continue
Posts: 91 | Registered: Oct 2004
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
- Just Put out Today...
